Climate change is expanding dengue fever's reach into previously unaffected regions, making effective vaccination strategies increasingly critical for protecting vulnerable populations. Real-world vaccine performance data has been scarce despite regulatory approvals, leaving public health officials operating with limited evidence during outbreak responses.
A large-scale analysis of 92,621 adolescents in São Paulo state during Brazil's 2024 dengue outbreak reveals that TAK-003 vaccination reduced symptomatic dengue infection by 50.2% after one dose and 61% after two doses. The study employed a test-negative design, comparing vaccinated teens who developed confirmed dengue against those with similar fever symptoms who tested negative. This methodology provides robust real-world effectiveness estimates by controlling for healthcare-seeking behavior and testing patterns during active disease surveillance.
This evidence fills a crucial gap in dengue prevention strategy. Previous vaccine development efforts faced significant setbacks, with Dengvaxia withdrawn from some markets due to safety concerns in dengue-naive populations. TAK-003's moderate but meaningful protection rate positions it as a valuable public health tool, particularly in endemic regions experiencing intensifying transmission due to urbanization and warming temperatures. However, the 61% effectiveness after two doses, while clinically significant, falls short of the protection levels seen with many childhood vaccines. The single-outbreak, single-age-group design also limits broader applicability. As dengue continues its geographic expansion, these effectiveness data will inform vaccination policies in the growing number of regions where dengue poses an emerging threat to adolescent populations.